Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $554.27 USD
Change Today +0.61 / 0.11%
Volume 697.0K
REGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 4:00 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

regeneron pharmaceuticals (REGN) Snapshot

Open
$558.47
Previous Close
$553.66
Day High
$561.31
Day Low
$546.00
52 Week High
07/20/15 - $569.91
52 Week Low
08/5/14 - $314.00
Market Cap
57.2B
Average Volume 10 Days
692.9K
EPS TTM
$3.34
Shares Outstanding
101.3M
EX-Date
--
P/E TM
166.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for REGENERON PHARMACEUTICALS (REGN)

regeneron pharmaceuticals (REGN) Details

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration (AMD) and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes comprising familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. The company’s trap-based clinical product candidates comprise EYLEA for the treatment of AMD and diabetic macular edema; and ZALTRAP for oncology. Its antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN727 for low-density lipoprotein cholesterol reduction and for the prevention of cardiovascular events; REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN668 for atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis; REGN2222 for respiratory syncytial virus; REGN1033 for skeletal muscle disorders; and REGN2176-3 and REGN910-3 antibodies for use in ophthalmology. The company is also developing REGN1908-1909, REGN1154, REGN1500, and REGN1193 antibody product candidates; REGN1400, REGN1979, and REGN2810 for oncology; and REGN475 for the treatment of pain. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA, as well as with Avalanche Biotechnologies, Inc. to discover, develop, and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.

3,066 Employees
Last Reported Date: 05/7/15
Founded in 1988

regeneron pharmaceuticals (REGN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $3.2M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $905.0K
Chief Scientific Officer, Director, Member of...
Total Annual Compensation: $2.7M
Executive Vice President of Research and Deve...
Total Annual Compensation: $1.0M
Senior Vice President of Commercial
Total Annual Compensation: $843.1K
Compensation as of Fiscal Year 2014.

regeneron pharmaceuticals (REGN) Key Developments

Sanofi and Regeneron Pharmaceuticals Announces Positive Phase III Results in Japanese Patients Treated with Praulent

Sanofi and Regeneron Pharmaceuticals announced results of a Phase III clinical study in Japanese patients treated with the investigational therapy Praluent (alirocumab), targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). The Phase III trial (ODYSSEY JAPAN) met its primary endpoint - demonstrating low-density lipoprotein cholesterol (LDL-C) - in Japanese patients with hypercholesterolaemia at high cardiovascular risk and/or with high-cholesterol owing to the medical condition heterozygous familial hypercholesterolaemia (HeFH). The 24-week trial involved 216 Japanese patients treated with Praulent alongside statins. Patient groups were administered with a dose of 75 mg initially. That dose was increased to 150 mg for two patients who failed to reach their LDL-C target by week 8. The mean LDL-C value at baseline was 141.2 mg/dL. Praluent demonstrated significant cholesterol-lowering ability with patients showing an average 64% reduction in LDL-C.

Regeneron Pharmaceuticals Wins Japanese Approval for EYLEA (Aflibercept) Injection for Treating Retinal Vein Occlusion

Regeneron Pharmaceuticals reported that they won approval for EYLEA (aflibercept) Injection in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO), a significant cause of vision impairment and a chronic disease that requires early and ongoing management to obtain the best possible vision. This approval was awarded to Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin Ltd, by the Ministry of Health, Labour and Welfare (MHLW). This Japanese approval is based on positive results from the company's double-masked, randomized, active-controlled phase 3 VIBRANT study in patients with visual impairment due to macular edema secondary to BRVO. The company stated the primary endpoint was the proportion of subjects who gained at least 15 letters in best corrected visual acuity (BCVA) from baseline at week 24, as measured on the Early Treatment Diabetic Retinopathy Scale (ETDRS) eye chart, a standard chart used in research to measure visual acuity.

Regeneron Pharmaceuticals, Inc. Approves Amendment to Certificate of Incorporation

Regeneron Pharmaceuticals, Inc. announced that at the annual meeting of shareholders held on June 12, 2015 approved an amendment to the company's certificate of incorporation to increase the number of authorized shares of capital stock and common stock.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REGN:US $554.27 USD +0.61

REGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $147.12 USD +0.85
Incyte Corp $103.98 USD -0.30
Kyowa Hakko Kirin Co Ltd ¥2,051 JPY +33.00
UCB SA €71.80 EUR +1.34
Vertex Pharmaceuticals Inc $136.99 USD +1.99
View Industry Companies
 

Industry Analysis

REGN

Industry Average

Valuation REGN Industry Range
Price/Earnings 100.0x
Price/Sales 18.5x
Price/Book 19.0x
Price/Cash Flow 160.7x
TEV/Sales 18.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENERON PHARMACEUTICALS, please visit www.regeneron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.